Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer medicine"
DOI: 10.1002/cam4.4681
Abstract: BACKGROUND Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active… read more here.
Keywords: study; nivolumab cabozantinib; progression nivolumab; cabozantinib ... See more keywords
Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33168
Abstract: In the article by Chen et al that accompanies this editorial, a quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic… read more here.
Keywords: quality; treatment; quality adjusted; cabozantinib ... See more keywords
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34126
Abstract: Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. The CABIR study aimed to identify… read more here.
Keywords: cabir study; cabozantinib; sequence; line ... See more keywords
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3283-z
Abstract: PurposeCabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC. Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR… read more here.
Keywords: cabozantinib plus; phase; erlotinib patients; cabozantinib ... See more keywords
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3349-y
Abstract: PurposeThis study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC).MethodsElectrocardiogram (12-lead ECG) measurements were obtained at screening, and at pre-dose, and 2, 4, and… read more here.
Keywords: phase; treatment; cabozantinib treatment; study ... See more keywords
Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2018 at "Targeted Oncology"
DOI: 10.1007/s11523-018-0559-0
Abstract: BackgroundCabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC).ObjectiveTo indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC.MethodsWe conducted a systematic literature review… read more here.
Keywords: risk; cabozantinib; treatment advanced; treatment ... See more keywords
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2020.102062
Abstract: Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient… read more here.
Keywords: renal cell; response; treatment; exposure ... See more keywords
Cabozantinib ameliorates lipopolysaccharide-induced lung inflammation and bleomycin--induced early pulmonary fibrosis in mice.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.108327
Abstract: The lung, as the primary organ for gas exchange in mammals, is the main target organ for many pathogens and allergens, which may cause acute lung injury. A certain proportion of acute lung injury may… read more here.
Keywords: lung injury; fibrosis; pulmonary fibrosis; cabozantinib ... See more keywords
Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.09.127
Abstract: Introduction: A significant portion of NSCLCs with MET proto‐oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping alterations are sensitive to small‐molecule mesenchymal‐epithelial transition tyrosine kinase inhibitors. However, the incidence and management of brain metastases… read more here.
Keywords: brain metastases; positive nsclc; exon positive; cabozantinib ... See more keywords
Modulating the function of ATP‐binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Sign Up to like & getrecommendations! Published in 2017 at "Pharmacological Research"
DOI: 10.1016/j.phrs.2017.01.024
Abstract: Graphical abstract Figure. No Caption available. ABSTRACT Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c‐Met and VEGFR2. Cabozantinib has been approved by the Food and Drug Administration to treat advanced… read more here.
Keywords: cabozantinib; atp binding; binding cassette; function atp ... See more keywords
Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Gene Therapy"
DOI: 10.1038/s41417-019-0098-6
Abstract: Cabozantinib is a multi-kinase inhibitor targeting MET, AXL, and VEGFR2, and has been approved for use in multiple malignancies. The means by which Cabozantinib acts to target colorectal cancer (CRC) cells remains poorly understood, and… read more here.
Keywords: crc cells; apoptosis; puma dependent; signaling pathway ... See more keywords